Literature DB >> 23100512

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

Krithika N Kodumudi1, Amy Weber, Amod A Sarnaik, Shari Pilon-Thomas.   

Abstract

Administration of nonmyeloablative chemotherapeutic agents or total body irradiation (TBI) prior to adoptive transfer of tumor-specific T cells may reduce or eliminate immunosuppressive populations such as T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSC). Little is known about these populations during immune reconstitution. This study was designed to understand the reconstitution rate and function of these populations post TBI in melanoma tumor-bearing mice. Reconstitution rate and suppressive activity of CD4(+)CD25(+)Foxp3(+) Tregs and CD11b(+)Gr1(+) MDSC following TBI-induced lymphopenia was measured in B16 melanoma tumor-bearing mice. To ablate the rapid reconstitution of suppressive populations, we treated mice with docetaxel, a known chemotherapeutic agent that targets MDSC, in combination with adoptive T cell transfer and dendritic cell immunotherapy. Both Treg and MDSC populations exhibited rapid reconstitution after TBI-induced lymphopenia. Although reconstituted Tregs were just as suppressive as Tregs from untreated mice, MDSC demonstrated enhanced suppressive activity of CD8(+) T cell proliferation compared with endogenous MDSC from tumor-bearing mice. TBI-induced lymphopenia followed by docetaxel treatment improved the efficacy of adoptive T cell transfer and dendritic cell immunotherapy in melanoma-bearing mice, inducing a significant reduction in tumor growth and enhancing survival. Tumor regression correlated with increased CTL activity and persistence of adoptively transferred T cells. Overall, these findings suggest that TBI-induced MDSC are highly immunosuppressive and blocking their rapid reconstitution may improve the efficacy of vaccination strategies and adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100512      PMCID: PMC3505990          DOI: 10.4049/jimmunol.1200274

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Development of antitumor immune responses in reconstituted lymphopenic hosts.

Authors:  Hong-Ming Hu; Christian H Poehlein; Walter J Urba; Bernard A Fox
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 2.  Tumor-induced immune dysfunctions caused by myeloid suppressor cells.

Authors:  V Bronte; P Serafini; E Apolloni; P Zanovello
Journal:  J Immunother       Date:  2001 Nov-Dec       Impact factor: 4.456

3.  A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard M Sherry; Francesco M Marincola; Susan F Leitman; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Azam Nahvi; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

4.  Determination of arginase activity in macrophages: a micromethod.

Authors:  I M Corraliza; M L Campo; G Soler; M Modolell
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

5.  Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Authors:  B Almand; J I Clark; E Nikitina; J van Beynen; N R English; S C Knight; D P Carbone; D I Gabrilovich
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

6.  Recent trends in cutaneous melanoma incidence among whites in the United States.

Authors:  A Jemal; S S Devesa; P Hartge; M A Tucker
Journal:  J Natl Cancer Inst       Date:  2001-05-02       Impact factor: 13.506

7.  Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.

Authors:  Manuelle Viguier; Fabrice Lemaître; Olivier Verola; Min-Sun Cho; Guy Gorochov; Louis Dubertret; Hervé Bachelez; Philippe Kourilsky; Laurent Ferradini
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 8.  Immature myeloid cells and cancer-associated immune suppression.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2002-04-24       Impact factor: 6.968

9.  Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Authors:  Sergei Kusmartsev; Yulia Nefedova; Daniel Yoder; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

10.  Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.

Authors:  B K Cho; V P Rao; Q Ge; H N Eisen; J Chen
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  52 in total

1.  Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.

Authors:  Brittany L Bunch; Krithika N Kodumudi; Ellen Scott; Jennifer Morse; Amy Mackay Weber; Anders E Berglund; Shari Pilon-Thomas; Joseph Markowitz
Journal:  Cancer Immunol Immunother       Date:  2020-06-18       Impact factor: 6.968

Review 2.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

3.  Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation.

Authors:  Zhi-Chun Ding; David H Munn; Gang Zhou
Journal:  Oncoimmunology       Date:  2014-08-03       Impact factor: 8.110

Review 4.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 5.  Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Authors:  Carole Fournier; François Martin; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Lionel Apetoh
Journal:  Oncoimmunology       Date:  2017-08-11       Impact factor: 8.110

6.  Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.

Authors:  Sebastian Kobold; Simon Grassmann; Michael Chaloupka; Christopher Lampert; Susanne Wenk; Fabian Kraus; Moritz Rapp; Peter Düwell; Yi Zeng; Jan C Schmollinger; Max Schnurr; Stefan Endres; Simon Rothenfußer
Journal:  J Natl Cancer Inst       Date:  2015-06-23       Impact factor: 13.506

7.  The calcineurin-NFAT axis controls allograft immunity in myeloid-derived suppressor cells through reprogramming T cell differentiation.

Authors:  Xiao Wang; Yujing Bi; Lixiang Xue; Jiongbo Liao; Xi Chen; Yun Lu; Zhengguo Zhang; Jian Wang; Huanrong Liu; Hui Yang; Guangwei Liu
Journal:  Mol Cell Biol       Date:  2014-12-01       Impact factor: 4.272

8.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

Review 9.  Pathways and therapeutic targets in melanoma.

Authors:  Emma Shtivelman; Michael Q A Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T Flaherty; David E Fisher
Journal:  Oncotarget       Date:  2014-04-15

10.  Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.

Authors:  Tomar Ghansah; Nasreen Vohra; Kathleen Kinney; Amy Weber; Krithika Kodumudi; Gregory Springett; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  Cancer Immunol Immunother       Date:  2013-04-19       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.